Product Image
Please see full prescribing and safety information, including boxed warning, for DOXOrubicin vials.

Available in:

  • 10 mg per 5 mL single-dose vials
  • 50 mg per 25 mL single-dose vials
  • 200 mg per 100 mL multi-dose vials

Benefits:

  • AP Rated
  • Preservative-free
  • Not made with natural rubber latex

DOXOrubicin Hydrochloride Injection, USP*

Brand Name Equivalent: ADRIAMYCIN® (ADRIAMYCIN is a registered trademark of Pharmacia & Upjohn Company.)
Therapeutic Category: Antineoplastic Agent

PreventIV MeasuresTM Features:

  • Easy-to-read drug name and dosage strength to aid in identifying the right product
  • Bar codes included on the vial and carton for ease of scanning
  • Unique label design to help products stand out on the shelf
  • Yellow and black cytotoxic caution flag designed to alert healthcare workers who handle the product
  • Enhanced packaging and labeling designed to promote safety and help reduce the risk of medication errors
  • Tall Man lettering to help caregivers avoid confusion with other drugs having look-alike names
NDC
#25021
Description Strength Fill
Volume
Concentration Container
Size
Closure Unit
of Sale
207-05 Glass Vial 10 mg 5 mL 2 mg per mL 5 mL 20 mm 10
207-25 Glass Vial 50 mg 25 mL 2 mg per mL 30 mL 20 mm 1
207-51 Glass Vial 200 mg 100 mL 2 mg per mL 100 mL 20 mm 1
WARNING: CARDIOMYOPATHY, SECONDARY MALIGNANCIES, EXTRAVASATION AND TISSUE NECROSIS, and SEVERE MYELOSUPPRESSION
    • Cardiomyopathy: Myocardial damage, including acute left ventricular failure can occur with doxorubicin HCl. The risk of cardiomyopathy is proportional to the cumulative exposure with incidence rates from 1% to 20% for cumulative doses ranging from 300 mg/m2 to 500 mg/m2 when doxorubicin HCl is administered every 3 weeks. The risk of cardiomyopathy is further increased with concomitant cardiotoxic therapy. Assess LVEF before and regularly during and after treatment with doxorubicin HCl [see Warnings and Precautions (5.1)].
    • Secondary Malignancies: Secondary acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) occur at a higher incidence in patients treated with anthracyclines, including doxorubicin HCl [see Warnings and Precautions (5.2)].
    • Extravasation and Tissue Necrosis: Extravasation of doxorubicin HCl can result in severe local tissue injury and necrosis requiring wide excision of the affected area and skin grafting. Immediately terminate the drug and apply ice to the affected area [see Warnings and Precautions (5.3)].
    • Severe myelosuppression resulting in serious infection, septic shock, requirement for transfusions, hospitalization, and death may occur [see Warnings and Precautions (5.4)].